[Comment] Genetic insights into moderate-to-severe asthma

Research paper by Rachel Nadif

Indexed on: 23 Dec '18Published on: 11 Dec '18Published in: The Lancet Respiratory Medicine


Asthma is a heterogeneous disease, composed of many phenotypes that have common clinical characteristics but which have different risk factors and responses to treatment. 5–10% of people with asthma are considered to have severe asthma, which is often associated with poor control and response to treatment. Severe asthma is itself a heterogeneous disease encompassing several clinical phenotypes that might share common pathophysiological mechanisms, so-called asthma endotypes.1 New therapies targeting specific pathways have been approved for severe asthma (eg, anti-IgE and anti-interleukin 5), and others directed against type 2 cytokines are being investigated,2 but the results have not always met expectations—eg, tralokinumab for interleukin 13.